Johnson & Johnson (NYSE:JNJ) Shares Bought by Vision Capital Management Inc.

Vision Capital Management Inc. grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 50,965 shares of the company’s stock after acquiring an additional 294 shares during the period. Johnson & Johnson comprises about 1.2% of Vision Capital Management Inc.’s holdings, making the stock its 26th biggest position. Vision Capital Management Inc.’s holdings in Johnson & Johnson were worth $7,988,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Hibernia Wealth Partners LLC acquired a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $27,000. FNY Investment Advisers LLC acquired a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $37,000. Tower View Wealth Management LLC raised its position in shares of Johnson & Johnson by 183.3% during the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 165 shares during the last quarter. Creative Capital Management Investments LLC raised its position in shares of Johnson & Johnson by 43.0% during the 3rd quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock worth $45,000 after purchasing an additional 86 shares during the last quarter. Finally, VitalStone Financial LLC acquired a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $48,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have weighed in on JNJ shares. Wells Fargo & Company downgraded Johnson & Johnson from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $170.00 to $163.00 in a report on Wednesday, December 13th. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday, February 28th. Raymond James boosted their price target on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. UBS Group upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their price target for the company from $167.00 to $180.00 in a report on Friday, December 1st. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Seven equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $177.31.

Johnson & Johnson Stock Up 1.4 %

Shares of Johnson & Johnson stock opened at $157.96 on Thursday. The company has a fifty day moving average price of $158.76 and a 200 day moving average price of $156.69. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. Johnson & Johnson has a twelve month low of $144.95 and a twelve month high of $175.97. The stock has a market cap of $380.65 billion, a price-to-earnings ratio of 11.44, a price-to-earnings-growth ratio of 2.62 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The firm had revenue of $21.40 billion during the quarter, compared to analysts’ expectations of $21.02 billion. During the same period in the prior year, the company earned $2.35 EPS. The firm’s revenue was down 9.7% on a year-over-year basis. Equities research analysts forecast that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th were given a dividend of $1.19 per share. The ex-dividend date was Friday, February 16th. This represents a $4.76 dividend on an annualized basis and a yield of 3.01%. Johnson & Johnson’s dividend payout ratio (DPR) is 34.47%.

Insider Buying and Selling

In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the transaction, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.